CorMedix Q4 2022 Earnings Report
Key Takeaways
CorMedix reported a net loss of $8.2 million, or $0.20 per share, for the fourth quarter of 2022, compared to a net loss of $7.8 million, or $0.20 per share, for the fourth quarter of 2021. The increase in net loss was primarily driven by increases in costs related to market research studies and pre-launch activities.
FDA granted CorMedix's meeting request and classified it as a Type A, allowing the company to seek FDA's guidance in mid-April.
The CorMedix team has made solid progress on all fronts, working diligently in support of the primary CMO as it completed the corrective actions to address previously identified deficiencies.
The company continues to build out the team, processes and systems to be ready for commercialization as quickly as possible following a potential FDA approval.
CorMedix has further refined its parallel supply chain pathways to mitigate risk, with the goal of pursuing FDA approval of DefenCath in 2023.